Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, March 12, 2024

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

 Didn't your competent? doctor start using this years ago? Oh, you don't have a competent doctor, do you?

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

VAN NUYS, Calif.--(BUSINESS WIRE)--Mar 12, 2024--

The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code for the IpsiHand™ Upper Extremity Rehabilitation System by Neurolutions, Inc. This significant decision marks the first time a brain-computer interface (BCI) controlled therapy has been recognized with the receipt of a HCPCS code, setting a new benchmark for thought-activated controlled devices.

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits. Utilizing BCI technology, the IpsiHand enables stroke survivors to engage in thought-actuated therapy, connecting movement to the intent to move signals within the brain, helping rebuild neuronal pathways.

CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME). This classification highlights the IpsiHand’s durability and appropriateness for home use, further emphasizing its role in advancing patient care and recovery outcomes. Neurolutions CEO, Leo Petrossian, expressed enthusiasm over the CMS decision, stating:

“We thank CMS for their decision and commitment to improving outcomes for stroke survivors by establishing a new HCPCS code, and for their support throughout the entire application process. This important milestone is a testament to the innovative spirit at Neurolutions, and a significant shift toward enhancing access to advanced rehabilitation technologies for stroke survivors across the nation.”

This is a step forward to establishing coverage for upper extremity rehabilitation therapies, opening the door for advancements in therapeutic BCI to generate better outcomes for patients and potentially lower the cost of care. Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

About Neurolutions, Inc.

Neurolutions is a medical technology company dedicated to transforming the lives of patients suffering from neurological conditions. Our mission is to develop innovative solutions that address the unmet needs of patients while advancing the field of neurorehabilitation through cutting-edge research and development.

The IpsiHand System is a breakthrough therapeutic device that uses brain-computer interface technology to help chronic stroke patients with an impaired upper extremity regain movement. The IpsiHand device has been clinically validated and has received FDA clearance for use in the United States.

No comments:

Post a Comment